Literature DB >> 21462262

Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy.

Martin Köllensperger1, Florian Krismer1, Anton Pallua1, Nadia Stefanova1, Werner Poewe1, Gregor K Wenning1.   

Abstract

Multiple system atrophy is a rapidly progressive neurodegenerative disorder with a markedly reduced life expectancy. Failure of symptomatic treatment raises an urgent need for disease-modifying strategies. We have investigated the neuroprotective potential of erythropoietin in (proteolipid protein)-α-synuclein transgenic mice exposed to 3-nitropropionic acid featuring multiple system atrophy-like pathology including oligodendroglial α-synuclein inclusions and selective neuronal degeneration. Mice were treated with erythropoietin starting before (early erythropoietin) and after (late erythropoietin) intoxication with 3-nitropropionic acid. Nonintoxicated animals receiving erythropoietin and intoxicated animals treated with saline served as control groups. Behavioral tests included pole test, open field activity, and motor behavior scale. Immunohistochemistry for tyrosine hydroxylase and dopamine and cyclic adenosine monophosphate-regulated phosphoprotein (DARPP-32) was analyzed stereologically. Animals receiving erythropoietin before and after 3-nitropropionic acid intoxication scored significantly lower on the motor behavior scale and they performed better in the pole test than controls with no significant difference between early and late erythropoietin administration. Similarly, rearing scores were worse in 3-nitropropionic acid-treated animals with no difference between the erythropoietin subgroups. Immunohistochemistry revealed significant attenuation of 3-nitropropionic acid-induced loss of tyrosine hydroxylase and DARPP-32 positive neurons in substantia nigra pars compacta and striatum, respectively, in both erythropoietin-treated groups without significant group difference in the substantia nigra. However, at striatal level, a significant difference between early and late erythropoietin administration was observed. In the combined (proteolipid protein)-α-synuclein 3-nitropropionic acid multiple system atrophy mouse model, erythropoietin appears to rescue dopaminergic and striatal gabaergic projection neurons. This effect is associated with improved motor function. Further studies are warranted to develop erythropoietin as a potential interventional therapy in multiple system atrophy.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21462262      PMCID: PMC4730556          DOI: 10.1002/mds.23474

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  52 in total

1.  Erythropoietin deficiency and anaemia in multiple system atrophy.

Authors:  A S Winkler; J Marsden; M Parton; P J Watkins; K R Chaudhuri
Journal:  Mov Disord       Date:  2001-03       Impact factor: 10.338

2.  Neuroprotection and Angiogenesis: Dual Role of Erythropoietin in Brain Ischemia.

Authors:  Hugo H. Marti; Myriam Bernaudin; Edwige Petit; Christian Bauer
Journal:  News Physiol Sci       Date:  2000-10

3.  Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus.

Authors:  Jérémie Nadam; Fabrice Navarro; Pascal Sanchez; Colette Moulin; Béatrice Georges; Aël Laglaine; Jean-Marc Pequignot; Anne Morales; Philippe Ryvlin; Laurent Bezin
Journal:  Neurobiol Dis       Date:  2006-12-12       Impact factor: 5.996

4.  Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production.

Authors:  S Genc; F Kuralay; K Genc; M Akhisaroglu; S Fadiloglu; K Yorukoglu; M Fadiloğlu; A Gure
Journal:  Neurosci Lett       Date:  2001-02-02       Impact factor: 3.046

5.  Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue.

Authors:  Robert Rotter; Marija Menshykova; Tobias Winkler; Georg Matziolis; Ioannis Stratos; Matthias Schoen; Thomas Bittorf; Thomas Mittlmeier; Brigitte Vollmar
Journal:  J Orthop Res       Date:  2008-12       Impact factor: 3.494

6.  Localization of specific erythropoietin binding sites in defined areas of the mouse brain.

Authors:  M Digicaylioglu; S Bichet; H H Marti; R H Wenger; L A Rivas; C Bauer; M Gassmann
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

7.  Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin.

Authors:  Asim Mahmood; Dunyue Lu; Changsheng Qu; Anton Goussev; Zheng Gang Zhang; Chang Lu; Michael Chopp
Journal:  J Neurosurg       Date:  2007-08       Impact factor: 5.115

8.  Survival in multiple system atrophy.

Authors:  Anette Schrag; Gregor K Wenning; Niall Quinn; Yoav Ben-Shlomo
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

9.  Immunohistochemical localization of erythropoietin and its receptor in the developing human brain.

Authors:  S E Juul; A T Yachnis; A M Rojiani; R D Christensen
Journal:  Pediatr Dev Pathol       Date:  1999 Mar-Apr

10.  Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative.

Authors:  J-L Cayla; P Maire; A Duvallet; J P Wahrmann
Journal:  Int J Sports Med       Date:  2007-12-17       Impact factor: 3.118

View more
  8 in total

1.  Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.

Authors:  Jinling Hou; Shaohui Wang; Yan Chen Shang; Zhao Zhong Chong; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2011-08-01       Impact factor: 1.990

2.  Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.

Authors:  Yan Chen Shang; Zhao Zhong Chong; Shaohui Wang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2011-11       Impact factor: 1.990

3.  Long-term moderate dose exogenous erythropoietin treatment protects from intermittent hypoxia-induced spatial learning deficits and hippocampal oxidative stress in young rats.

Authors:  Jobran M Al-Qahtani; Basel A Abdel-Wahab; Samy M Abd El-Aziz
Journal:  Neurochem Res       Date:  2013-11-20       Impact factor: 3.996

Review 4.  New insights into atypical parkinsonism.

Authors:  Gregor K Wenning; Florian Krismer; Werner Poewe
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

5.  PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

6.  Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL.

Authors:  Yan Chen Shang; Zhao Zhong Chong; Shaohui Wang; Kenneth Maiese
Journal:  Aging (Albany NY)       Date:  2012-03       Impact factor: 5.682

Review 7.  Animal modeling an oligodendrogliopathy--multiple system atrophy.

Authors:  Jonathan M Bleasel; Glenda M Halliday; Woojin Scott Kim
Journal:  Acta Neuropathol Commun       Date:  2016-02-09       Impact factor: 7.801

Review 8.  Erythropoietin: new directions for the nervous system.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Int J Mol Sci       Date:  2012-09-06       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.